AstraZeneca Says ZEGFROVY 200 Mg Administered Orally Once Daily Now Available In US

By Reuters News

- AstraZeneca PLC AZN.L:

  • ZEGFROVY® (SUNVOZERTINIB) NOW AVAILABLE IN THE US FOR PATIENTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS

  • ASTRAZENECA - ZEGFROVY 200 MG ADMINISTERED ORALLY ONCE DAILY NOW AVAILABLE IN US

Further company coverage: AZN.L

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk